TY - JOUR
TI - L1CAM expression in colorectal cancer identifies a high-risk group of patients with dismal prognosis already in early-stage disease
AU - Tampakis, A.
AU - Tampaki, E.C.
AU - Nonni, A.
AU - Tsourouflis, G.
AU - Posabella, A.
AU - Patsouris, E.
AU - Kontzoglou, K.
AU - von Flüe, M.
AU - Nikiteas, N.
AU - Kouraklis, G.
JO - Acta Oncologica
PY - 2020
VL - 59
TODO - 1
SP - 55-59
PB - Taylor and Francis Ltd.
SN - 0284-186X, 1651-226X
TODO - 10.1080/0284186X.2019.1667022
TODO - cell adhesion molecule;  l1 cell adhesion molecule;  unclassified drug;  L1CAM protein, human;  nerve cell adhesion molecule L1;  tumor marker, Article;  cancer patient;  cancer prognosis;  cancer staging;  cancer survival;  colorectal cancer;  controlled study;  distant metastasis;  early cancer;  high risk population;  human;  human tissue;  immunohistochemistry;  lymph node metastasis;  major clinical study;  overall survival;  priority journal;  progression free survival;  protein expression;  biosynthesis;  colorectal tumor;  disease exacerbation;  metabolism;  metastasis;  pathology;  prognosis;  risk assessment;  survival rate;  tumor recurrence, Biomarkers, Tumor;  Colorectal Neoplasms;  Disease Progression;  Humans;  Immunohistochemistry;  Neoplasm Metastasis;  Neoplasm Recurrence, Local;  Neoplasm Staging;  Neural Cell Adhesion Molecule L1;  Prognosis;  Progression-Free Survival;  Risk Assessment;  Survival Rate
TODO - Background: Metastatic disease in colorectal cancer represents a major cause of significant cancer-associated morbidity and mortality. L1CAM is a stem cell marker, cell adhesion molecule, belongs to the immunoglobulin superfamily of cell adhesion molecules (IgCAM) and it is aberrantly expressed in several different types of human solid tumors. The aim of the present study was to assess the expression patterns of L1CAM and its clinical significance in colorectal cancer. Patients and methods: Surgical specimens of 109 patients with primary resectable colorectal cancer were examined for L1CAM expression via immunohistochemistry and the results were correlated with clinical and survival data. Results: L1CAM expression was significantly correlated with advanced stage of disease (p <.001), higher T classification (p =.040), the presence of lymph node (p <.001) and distant metastasis (p =.011). Patients displaying high L1CAM expression demonstrated a dismal three-year progression free survival (29.7% vs 87.1%, p <.001) and five-year overall survival (39.9% vs 87.7%, p <.001). Multivariate analysis using Cox proportional hazard models revealed high L1CAM expression as a prognostic marker of dismal progression free (HR 0.187, 95%CI = 0.075–0.467, p <.0001) and overall survival (HR 0.154, 95%CI = 0.049–0.483, p =.001) independent of other clinicopathological characteristics. Subgroup analysis comprised of patients with early stage disease only presented as well significantly worse progression free and overall survival when L1CAM exhibited high expression. Conclusions: Colorectal cancer patients displaying high expression of L1CAM harbor high risk for metastasis already in early stage disease identifying therefore a group of patients prone to dismal prognosis. © 2019, © 2019 Acta Oncologica Foundation.
ER -